Progression independent of relapse activity (PIRA) in relapsing-remitting multiple sclerosis patients on first-line immunomodulatory treatment with fingolimod vs. platform injectables

被引：0
|
作者：
von Wyl, V. [1 ]
Benkert, P. [2 ]
Lorscheider, J. [3 ,4 ]
Hanni, P. [5 ]
Lienert, C. [6 ]
Decard, B. [3 ,4 ]
Kuhle, J. [3 ,4 ]
Derfuss, T. [3 ,4 ]
Kappos, L. [3 ,4 ]
Yaldizli, O. [3 ,4 ]
机构：
[1] Univ Zurich, Dept Epidemiol Biostat & Prevent, Zurich, Switzerland
[2] Univ Hosp Basel, Dept Clin Res, Clin Trial Unit, Basel, Switzerland
[3] Univ Hosp Basel, Dept Med, Neurol Clin & Policlin, Basel, Switzerland
[4] Univ Basel, Basel, Switzerland
[5] Swiss Assoc Joint Tasks Hlth Insurers, Solothurn, Switzerland
[6] Rheinburg Clin, Dept Neurol, Walzenhausen, Switzerland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
基金：
新加坡国家研究基金会;
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P751
引用
收藏
页码：381 / 382
页数：2
相关论文
共 50 条
  • [21] Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosis
    Koch, Marcus W.
    Mostert, Jop
    Repovic, Pavle
    Bowen, James D.
    Wolinsky, Jerry S.
    Lublin, Fred D.
    Strijbis, Eva
    Cutter, Gary
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (04) : 1106 - 1116
  • [22] Motor evoked potentials predict progression independent of relapse activity (PIRA) in relapsing multiple sclerosis
    Michal, Zido
    Hofer, Lisa
    Benkert, Pascal
    Schadelin, Sabine
    Kuhle, Jens
    Hardmeier, Martin
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 168 - 169
  • [23] Fingolimod: A potential first-in-class oral therapy for the treatment of relapsing-remitting multiple sclerosis
    Sobieraj, Diana M.
    FORMULARY, 2010, 45 (08) : 245 - 251
  • [24] Teriflunomide: an oral therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis
    Dalla Costa, Gloria
    Comi, Giancarlo
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2023, 23 (08) : 681 - 687
  • [25] Clinical and Demographic Predictors of Response to First-Line Therapies in Relapsing-Remitting Multiple Sclerosis
    Castillo-Trivino, Tamara
    Gajofatto, Alberto
    Waubant, Emmanuelle
    NEUROLOGY, 2011, 76 (09) : A72 - A72
  • [26] Real-world persistence to first-line DMTs in relapsing-remitting multiple sclerosis
    Lopez-Caneda, Clara
    Perez-Haro, Maria Jose
    Sanchez-Franco, Cesar
    Alvarez-Rodriguez, Elena
    Aguado-Valcarcel, Marta
    Marcos-Bobillo, Maria
    Gonzalez-Suarez, Ines
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 78
  • [27] Pilot results of a web based patient decision aid for first-line treatment of relapsing-remitting multiple sclerosis patients
    Lapointe, E.
    Bansback, N.
    Chiu, J. A.
    Traboulsee, A.
    Carruthers, R.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 411 - 412
  • [28] Characteristics of Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Switching First-Line Therapies for Different Reasons
    Teter, Barbara
    Agashivala, Neetu
    Hashmonay, Ron
    Weinstock-Guttman, Bianca
    NEUROLOGY, 2013, 80
  • [29] Predictive factors of response to first-line immunomodulatory treatment in patients with relapsing-remitting multiple sclerosis: evaluation of the first two years of treatment in an Italian single-centre study
    Romeo, M.
    Rodegher, M.
    Boneschi, F. Martinelli
    Martinelli, V.
    Radaelli, M.
    Straffi, L.
    Comi, G.
    JOURNAL OF NEUROLOGY, 2010, 257 : S149 - S149
  • [30] Microglial activation associates with previous relapse activity in a cohort of relapsing-remitting multiple sclerosis patients at risk of progression
    Laaksonen, S.
    Sucksdorff, M.
    Matilainen, M.
    Airas, L.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 600 - 601
12345